JP7587275B2 - 筋萎縮性側索硬化症の治療方法または予防方法 - Google Patents

筋萎縮性側索硬化症の治療方法または予防方法 Download PDF

Info

Publication number
JP7587275B2
JP7587275B2 JP2021511593A JP2021511593A JP7587275B2 JP 7587275 B2 JP7587275 B2 JP 7587275B2 JP 2021511593 A JP2021511593 A JP 2021511593A JP 2021511593 A JP2021511593 A JP 2021511593A JP 7587275 B2 JP7587275 B2 JP 7587275B2
Authority
JP
Japan
Prior art keywords
composition
subject
aspa
use according
als
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021511593A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020047368A5 (https=
JP2021535168A5 (https=
JP2021535168A (ja
Inventor
ジェレミー フランシス，
パオラ レオーネ，
Original Assignee
ローワン・ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ローワン・ユニバーシティ filed Critical ローワン・ユニバーシティ
Publication of JP2021535168A publication Critical patent/JP2021535168A/ja
Publication of JPWO2020047368A5 publication Critical patent/JPWO2020047368A5/ja
Publication of JP2021535168A5 publication Critical patent/JP2021535168A5/ja
Priority to JP2024091954A priority Critical patent/JP7807105B2/ja
Application granted granted Critical
Publication of JP7587275B2 publication Critical patent/JP7587275B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01015—Aspartoacylase (3.5.1.15)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021511593A 2018-08-30 2019-08-30 筋萎縮性側索硬化症の治療方法または予防方法 Active JP7587275B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024091954A JP7807105B2 (ja) 2018-08-30 2024-06-06 筋萎縮性側索硬化症の治療方法または予防方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862724780P 2018-08-30 2018-08-30
US62/724,780 2018-08-30
PCT/US2019/048985 WO2020047368A1 (en) 2018-08-30 2019-08-30 Methods of treating or preventing amyotrophic lateral sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024091954A Division JP7807105B2 (ja) 2018-08-30 2024-06-06 筋萎縮性側索硬化症の治療方法または予防方法

Publications (4)

Publication Number Publication Date
JP2021535168A JP2021535168A (ja) 2021-12-16
JPWO2020047368A5 JPWO2020047368A5 (https=) 2022-06-13
JP2021535168A5 JP2021535168A5 (https=) 2022-06-13
JP7587275B2 true JP7587275B2 (ja) 2024-11-20

Family

ID=69643060

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021511593A Active JP7587275B2 (ja) 2018-08-30 2019-08-30 筋萎縮性側索硬化症の治療方法または予防方法
JP2024091954A Active JP7807105B2 (ja) 2018-08-30 2024-06-06 筋萎縮性側索硬化症の治療方法または予防方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024091954A Active JP7807105B2 (ja) 2018-08-30 2024-06-06 筋萎縮性側索硬化症の治療方法または予防方法

Country Status (9)

Country Link
US (2) US12508327B2 (https=)
EP (1) EP3844285A4 (https=)
JP (2) JP7587275B2 (https=)
KR (1) KR20210053305A (https=)
CN (1) CN112673107A (https=)
AU (2) AU2019328337B2 (https=)
CA (1) CA3107612A1 (https=)
IL (1) IL280965B2 (https=)
WO (1) WO2020047368A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024133479A (ja) * 2018-08-30 2024-10-02 ローワン・ユニバーシティ 筋萎縮性側索硬化症の治療方法または予防方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240562A1 (en) * 2024-05-15 2025-11-20 Woolsey Pharmaceuticals, Inc. Method of treating amyotrophic lateral sclerosis with trimetazidine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504088A (ja) 2007-11-20 2011-01-27 ヴァレオ システム ドゥ コントロール モトゥール 昇圧回路
JP2013531471A (ja) 2010-04-23 2013-08-08 ユニバーシティ オブ マサチューセッツ Ｃｎｓターゲティングａａｖベクターおよびその使用方法
US20130323229A1 (en) 2012-05-30 2013-12-05 University Of Medicine And Dentistry Of New Jersey Metabolic therapy for oxidative stress in the brain through targeted neuronal catabolism of n-acetyl-aspartic acid
WO2017181105A1 (en) 2016-04-15 2017-10-19 University Of Massachusetts Methods and compositions for treating metabolic imbalance

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2753379B1 (fr) * 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
EP3844285A4 (en) 2018-08-30 2022-06-29 Rowan University Methods of treating or preventing amyotrophic lateral sclerosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504088A (ja) 2007-11-20 2011-01-27 ヴァレオ システム ドゥ コントロール モトゥール 昇圧回路
JP2013531471A (ja) 2010-04-23 2013-08-08 ユニバーシティ オブ マサチューセッツ Ｃｎｓターゲティングａａｖベクターおよびその使用方法
US20130323229A1 (en) 2012-05-30 2013-12-05 University Of Medicine And Dentistry Of New Jersey Metabolic therapy for oxidative stress in the brain through targeted neuronal catabolism of n-acetyl-aspartic acid
WO2017181105A1 (en) 2016-04-15 2017-10-19 University Of Massachusetts Methods and compositions for treating metabolic imbalance

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Arch Neurol.，2011年，Vol. 68, No. 10，pp. 1308-1312
J. Med. Chem.，2009年，Vol. 52，pp. 5442-5448
Neurological Research，2012年，Vol. 34, No. 3，pp. 297-303

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024133479A (ja) * 2018-08-30 2024-10-02 ローワン・ユニバーシティ 筋萎縮性側索硬化症の治療方法または予防方法
US12508327B2 (en) 2018-08-30 2025-12-30 Rowan University Methods of treating or preventing amyotrophic lateral sclerosis
JP7807105B2 (ja) 2018-08-30 2026-01-27 ローワン・ユニバーシティ 筋萎縮性側索硬化症の治療方法または予防方法

Also Published As

Publication number Publication date
CA3107612A1 (en) 2020-03-05
IL280965A (en) 2021-04-29
AU2019328337A1 (en) 2021-03-18
EP3844285A1 (en) 2021-07-07
US20260077060A1 (en) 2026-03-19
JP7807105B2 (ja) 2026-01-27
CN112673107A (zh) 2021-04-16
KR20210053305A (ko) 2021-05-11
US20210177989A1 (en) 2021-06-17
JP2021535168A (ja) 2021-12-16
WO2020047368A1 (en) 2020-03-05
IL280965B1 (en) 2025-02-01
US12508327B2 (en) 2025-12-30
AU2019328337B2 (en) 2025-04-17
JP2024133479A (ja) 2024-10-02
AU2025205072A1 (en) 2025-07-24
IL280965B2 (en) 2025-06-01
EP3844285A4 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
JP7761686B2 (ja) 操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法
RU2606012C2 (ru) Новая вирусная векторная конструкция для нейронспецифического оптимизированного непрерывного синтеза dopa in vivo
JP7807105B2 (ja) 筋萎縮性側索硬化症の治療方法または予防方法
US20250049955A1 (en) Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
BR112020010735A2 (pt) terapia genética para mucopolissacaridose iii a
US20230285596A1 (en) Compositions and methods for the treatment of niemann-pick type c1 disease
CN108431216A (zh) 经密码子优化的尺寸减小的atp7a cdna及用于治疗铜转运障碍的用途
TW202449149A (zh) 用於治療與葡萄糖神經醯胺酶β１缺陷相關之神經病症的組合物及方法
HK1168555A (en) Novel viral vector construct for neuron specific continuous dopa synthesis in vivo
HK1168555B (en) Novel viral vector construct for neuron specific continuous dopa synthesis in vivo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220602

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240606

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241031

R150 Certificate of patent or registration of utility model

Ref document number: 7587275

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150